Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other Non-Current Liabilities (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Other Non-Current Liabilities for 7 consecutive years, with $345000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 76.02% to $345000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $345000.0, a 76.02% increase, with the full-year FY2024 number at $193000.0, down 47.7% from a year prior.
  • Other Non-Current Liabilities was $345000.0 for Q3 2025 at 4D Molecular Therapeutics, up from $334000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $1.9 million in Q2 2021 to a low of $15000.0 in Q1 2022.
  • A 5-year average of $385263.2 and a median of $219000.0 in 2023 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 98.93% in 2022, then surged 1360.0% in 2023.
  • 4D Molecular Therapeutics' Other Non-Current Liabilities stood at $214000.0 in 2021, then fell by 0.93% to $212000.0 in 2022, then surged by 74.06% to $369000.0 in 2023, then crashed by 47.7% to $193000.0 in 2024, then surged by 78.76% to $345000.0 in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Other Non-Current Liabilities are $345000.0 (Q3 2025), $334000.0 (Q2 2025), and $322000.0 (Q1 2025).